Head-To-Head Review: Accolade (NASDAQ:ACCD) vs. CardioGenics (OTCMKTS:CGNH)

CardioGenics (OTCMKTS:CGNH) and Accolade (NASDAQ:ACCD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional & Insider Ownership

85.0% of Accolade shares are held by institutional investors. 41.4% of CardioGenics shares are held by insiders. Comparatively, 8.2% of Accolade shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for CardioGenics and Accolade, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Accolade	0	3	11	0	2.79

Accolade has a consensus target price of $8.96, suggesting a potential upside of 160.42%. Given Accolade’s stronger consensus rating and higher possible upside, analysts clearly believe Accolade is more favorable than CardioGenics.

Profitability

This table compares CardioGenics and Accolade’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Accolade	-18.16%	-18.43%	-10.35%

Earnings and Valuation

This table compares CardioGenics and Accolade”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Accolade	$441.03 million	0.63	-$99.81 million	($1.03)	-3.34

CardioGenics has higher earnings, but lower revenue than Accolade.

Summary

Accolade beats CardioGenics on 5 of the 9 factors compared between the two stocks.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Accolade

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.